1	Surveillance of seasonal respiratory viruses among Chilean patients during the					
2	COVID-19 pandemic.					
3						
4	Luis A. Alonso-Palomares ^{1,3,5*} , C. Joaquín Cáceres ⁶ , Rodrigo Tapia ² , Paulina Aguilera-					
5	Cortés ^{3,5} , Santiago Valenzuela ⁴ , Fernando Valiente-Echeverría ^{1,3,5} , Ricardo Soto-Rifo ^{1,3,5} ,					
6	Aldo Gaggero ^{1,4} , and Gonzalo P. Barriga ^{1,2#} .					
7						
8	¹ SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences,					
9	Faculty of Medicine, Universidad de Chile.					
10	² Laboratory of Emerging Viruses, Virology Program, Institute of Biomedical Sciences,					
11	Faculty of Medicine, Universidad de Chile					
12	³ Laboratory of Molecular and Cellular Virology, Virology Program, Institute of					
13	Biomedical Sciences, Faculty of Medicine, Universidad de Chile					
14	⁴ Laboratory of Environmental Virology, Virology Program, Institute of Biomedical					
15	Sciences, Faculty of Medicine, Universidad de Chile					
16	⁵ HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile					
17	⁶ Department of Population Health, College of Veterinary Medicine, University of					
18	Georgia, Athens, Georgia, USA					
19						
20						
21	# To whom correspondence should be addressed: Dr. Gonzalo Barriga,					
22	(gonzalo.barriga@uchile.cl), Emerging Viruses Laboratory, Virology Program, Institute of					
23	Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Independencia 1027,					
24	Santiago, Chile					
25						
26						
27						
28	Keywords: Surveillance, respiratory viruses, SARS-CoV-2, Influenza virus, RSV, Rhinovirus					
29						
30 21						
51						

32 The Study

33 SARS-CoV-2 has generated over 122 million cases worldwide. Non-pharmaceuticals 34 interventions such as confinements and lockdowns started in Chile on March 18th 2020. 35 In Europe, confinements and lockdowns have been accompanied by a decrease in the 36 circulation of other respiratory viruses such as Influenza A virus(IAV), Influenza B 37 virus(IBV) or respiratory syncytial virus(RSV) (1). Although changes in circulation 38 patterns of respiratory viruses have been reported, limited information regarding the 39 southern hemisphere is available where the SARS-CoV-2 pandemic merged with the 40 winter season. We conducted viral surveillance of respiratory viruses and we evaluated 41 their presence and establishing whether they were co-circulating with SARS-CoV-2.

42 Few south hemisphere countries reported the same pattern than Europe where non-43 pharmaceutical measures began before the winter season (2, 3) but to the best to our 44 knowledge, no report has been generated containing information from Chile. Here, we 45 collected 800 nasopharyngeal-swabs samples (NSS) from 13 health care centers 46 belonging to the north area of Santiago, Chile, between April 1st to July 31st, 2020 (Figure 47 1). All samples were collected from patients with at least one COVID-19 symptoms. 400 48 samples were determined as positive for SARS-CoV-2. 64% percent of SARS-CoV-2 49 positive individuals showed age range between 23-57 years. In addition, women had a 50 significant incidence of positive cases, corresponding to 59% in age range group (Figure 51 2).

52 Next, based on geographic location we divided the samples in 3 groups (A, B and C) 53 Figure 1. Location (A) contains the highest number of SARS-CoV-2 cases, contributing 54 more than 50% of the positive samples analyzed in this study (Figure 1). This high 55 positivity could be explained by the population density of location A, which contains at least 4-fold more inhabitants than locations B and C (Figure 1). Nevertheless, the health centers located in B presented positivity rates higher than 61% for SARS-CoV2 (Table 1), except for sub-locations 9 and 10 (Figure 1), where no positive samples were obtained in the period analyzed. Location C is farthest location form downtown, however, still has a positivity of 54.8% indicating a homogeneous distribution of SARS-CoV-2.

Taken together, our data show a high frequency of positive samples throughout the
healthcare centers evaluated suggesting the population density as a risk factor for SARSCoV-2 transmission since location A and B concentrates more population than location
C. These results demonstrate that the 2020 winter season in Santiago presented a high
incidence of SARS-CoV-2.

66 Then, we sought to determine in all samples whether SARS-CoV-2 was co-circulating 67 with other respiratory viruses. We chose predominant respiratory viruses in Santiago 68 (winter season), such as: IAV, IBV, RSV and human rhinovirus (HRV) (Table 1). 69 Adenovirus, Parainfluenza and Metapneumovirus were not evaluated since they are 70 considered all-year viruses (4). The results showed three samples with co-infection 71 between IAV and SARS-CoV-2 (Table 1). This is congruent to recent studies in Ecuador 72 and brazil showing complete decrease of IAV (5, 6). Despite the co-circulation or co-73 infection between IAV and SARS-CoV-2 observed, we could not detect RSV or IBV in the 74 SARS-CoV-2 positive samples. These results suggest an impact of the non-75 pharmaceutical interventions in the circulation of seasonal viruses, as previously 76 reported in Korea and Hong Kong (7, 8). Next, we evaluated the presence of IAV, IBV and 77 RSV in the samples reported as negative for SARS-CoV-2 where five positive samples for 78 IAV and no positive samples for IBV or RSV were detected, suggesting a circulation of 79 these viruses below 1% considering the amount of samples evaluated (Table 1). This is 80 lower than the information from the northern hemisphere where a range between 2-81 10% has been reported (9, 10). Taken together, these results suggest a lower co-82 circulation of IAV with SARS-CoV-2 and co-circulation below the level of detection of this 83 study for SARS-CoV-2 together with IBV or RSV.

84 Finally, we focused on HRV, responsible for more than 50% of the cold-like illnesses, with 85 a high preponderance to coinfection with other respiratory viral pathogens(11). 86 Furthermore, HRV was the predominant virus after SARS-CoV-2 detected either 87 cocirculating with SARS-CoV-2 or circulating alone(9). The presence of HRV was 88 assessed, showing that 0.25% of the samples were co-infected SARS-CoV-2/HRV. On the 89 other hand, the HRV co-circulation was 0.8% (Table 1). These results establish HRV co-90 circulation and the co-infection with SARS-CoV-2. Taken together, these results 91 demonstrate the displacement of seasonal respiratory viruses due to the presence of 92 SARS-CoV-2. Despite of this displacement, IAV and HRV are still able to keep 93 cocirculating together with SARS-CoV-2 but to a considerably lesser extent in 94 comparison with previous winter seasons.

95

96 **Discussion**

To gain insights into the potential co-circulation of the most relevant seasonally circulating respiratory viruses together with SARS-CoV-2, a fact on going COVID-19 pandemic was that the vast majority of the SARS-CoV-2 testing during the April-July period was indicated only with the presence of symptoms, we arbitrarily selected 200 samples per month (April to July) for a total of 800 NSS from 13 health care centers located in the north zone of Santiago, Chile. 103 We detected a high positivity rate by health care center between 30,4%-72% and we 104 observed at least twice co-infections between SARS-CoV-2/IAV or SARS-CoV-2/HRV and 105 no co-infections with IBV and RSV, which is in agreement with previously reported data 106 including the southern hemisphere (5,12). Furthermore, IAV and HRV were detected 107 from negative SARS-CoV-2 samples, whereas no presence of IBV or RSV was obtained 108 even from the negative SARS-CoV-2 samples (Table 1). These results demonstrate the 109 displacement of the predominant seasonal respiratory viruses, which have an essential 110 impact during the winter season caused by the high circulation rate of SARS-CoV-2. A 111 similar phenomenon was observed after the 2009 Influenza A (H1N1) pandemic, which 112 generated a decrease of RSV and IAV H3N2 infections (13). The reduction or absence of 113 IAV, IBV or RSV observed in this study can be explained by the non-pharmaceutical 114 interventions such as confinement and lockdowns established before the beginning of 115 the winter season in March 2020. A previous report showed that SARS-CoV-2 could 116 replace within three weeks the seasonal respiratory viruses circulating (1), while that 117 HRV co-infections are one of the most commonly observed. However, the impact that 118 HRV infection co-infecting with other respiratory viruses is still unclear due to 119 inconsistencies among different studies (11). The effect of HRV in SARS-CoV-2 infection 120 and the clinical outcome is still unknown.

121 Considering that the vast majority of the SARS-CoV-2 testing during the April-July period 122 was indicated only with the presence of symptoms, potential bacterial infections or co-123 infections cannot be ruled out in this study. The presence of bacterial infections during 124 the SARS-CoV-2 pandemic has been previously reported (14-16). A previous study 125 identified *S. Pneumoniae, K. pneumoniae and H. influenza* among the bacteria 126 cocirculating with SARS-CoV-2 (16). However, the detection of bacteria is beyond the127 scope of the study

128 In conclusion, the data shows the impact of SARS-CoV-2 over the co-circulation of 129 seasonal respiratory viruses like IAV, IBV, and RSV in Chile. Our results suggest that the 130 emergence of SARS-CoV-2 in addition with different non-pharmaceutical measures 131 adopted worldwide have a detrimental impact on the circulation at least of seasonal 132 respiratory viruses. Furthermore, our data allow us to foresee the circulation of 133 respiratory viruses in the 2021 winter season in the southern hemisphere.

135 **Conflict of interest**

136 The authors declare that there are no conflicts of interest associated with this work 137

138 Ethical statement

The study described here was approved by the Ethics Committee of the Faculty of Medicine at Universidad de Chile (Project Nº 036-2020). The samples were de-identified and not considered as human samples.

142

143 Acknowledgments and Funding

The authors are supported by Instituto Antártico Chileno (INACH) RT_35-19 (GB-P), ANID
Chile through Fondecyt grants № 11200228 (GB) 1181656 (AG), 1190156 (RS-R),
1180798 (FV-E); Postdoctoral fellowship N° SECTEI/138/2019 from Mexico City (LA-P).
Authors would like to thank the Science, Technology, Knowledge and Innovation
Ministry of Chile for articulating and coordinating support from the scientific
community. Also, we want to thank the diagnostic group of the University of Chile

150

151 Authors contributions.

Conceptualization: LAP, CJC and GB, Data curation: LAP, RT, PA, AG, FV-E and GB, Formal
analysis: LAP and GB, Funding acquisition: GB, Investigation: LAP, RT, PA, SV and GB,
Methodology: LAP, CJC, FAV-E, AG, RS-R and GB, Project administration: LAP, CJC, FV-E,
AG, RS-R and GB.

Supervision: LAP, FAV-E, AG, RS-R and GB, Validation: LAP, CJC, and GB, Visualization:
LAP, CJC, and GB, Writing-original & draft: CJC, and GB, Writing-review & editing: LAP,
CJC, FAV-E, AG, RS-R and GB, All authors approved the final version of the manuscript.
Gonzalo Barriga had full data access to all data in this study and takes complete
responsibility for the integrity of the data and the accuracy of the data analysis.

161

162 Transparency statement

Gonzalo Barriga affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained

167 Data availability statement

- 168 The authors confirm that the data supporting the findings of this study and its
- 169 supplementary materials.

171 **References**

172

Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegele K, Rentsch K, et al.
 Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory
 Viruses. J Infect Dis. 2020 Jul 29.

Ortiz-Prado E, Simbana-Rivera K, Barreno LG, Diaz AM, Barreto A, Moyano C, et
 al. Epidemiological, socio-demographic and clinical features of the early phase of the
 COVID-19 epidemic in Ecuador. PLoS Negl Trop Dis. 2021 Jan;15(1):e0008958.

3. Goes LGB, Zerbinati RM, Tateno AF, de Souza AV, Ebach F, Corman VM, et al.
Typical epidemiology of respiratory virus infections in a Brazilian slum. J Med Virol. 2020
Aug;92(8):1316-21.

Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral
 Infections. Annu Rev Virol. 2020 Mar 20.

184 5. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical
185 characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during
186 COVID-19 outbreak. J Med Virol. 2020 Jun 12.

Konala VM, Adapa S, Naramala S, Chenna A, Lamichhane S, Garlapati PR, et al. A
 Case Series of Patients Coinfected With Influenza and COVID-19. J Investig Med High
 Impact Case Rep. 2020 Jan-Dec;8:2324709620934674.

Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment
of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in
Hong Kong: an observational study. Lancet Public Health. 2020 May;5(5):e279-e88.

1938.Choe YJ, Lee JK. The Impact of Social Distancing on the Transmission of Influenza194Virus, South Korea, 2020. Osong Public Health Res Perspect. 2020 Jun;11(3):91-2.

Nowak MD, Sordillo EM, Gitman MR, Paniz Mondolfi AE. Co-infection in SARS CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus? J Med
 Virol. 2020 Apr 30.

10. Mutnal MB, Arroliga AC, Walker K, Mohammad A, Brigmon MM, Beaver RM, et
al. Early trends for SARS-CoV-2 infection in central and north Texas and impact on other
circulating respiratory viruses. J Med Virol. 2020 May 15.

11. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin
202 Microbiol Rev. 2013 Jan;26(1):135-62.

203 12. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2
204 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect Dis. 2020
205 Jun;26(6):1324-6.

Yang L, Chan KH, Suen LK, Chan KP, Wang X, Cao P, et al. Impact of the 2009 H1N1
Pandemic on Age-Specific Epidemic Curves of Other Respiratory Viruses: A Comparison
of Pre-Pandemic, Pandemic and Post-Pandemic Periods in a Subtropical City. PLoS One.
2015;10(4):e0125447.

Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid
review and meta-analysis. Clin Microbiol Infect. 2020 Jul 22.

Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community Acquired Coinfection in COVID-19: A Retrospective Observational Experience. Clin Infect Dis. 2020
Jul 1.

- 216 16. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory
- 217 pathogens among COVID-2019 cases. Virus Res. 2020 Aug;285:198005.



Figure 1: Geographical distribution of the samples analyzed in this study. Distribution of the thirteen-health care center from where the samples were obtained. The figure shows the number of samples by health care center (black number below white circle). Red flag shows health cares center with SARS-CoV-2 positive cases, green flag shows health cares with SARS-CoV-2 negative cases, the human shape indicate population by location (A, B and C).

- Table 1.- Co-circulation and co-infection of seasonal respiratory viruses together with
- 229 SARS-CoV-2 in the Northern area of Santiago, Chile.

Location	Health care center*	SARS-CoV-2	IAV	IBV	RSV	HRV	SARS-CoV-2/ IAV	SARS-CoV- 2/ HRV
А	1	82/140 (58.6%)	2/140	0	0	2/140	0	1/140
А	2	43/89 (49.4%)	0	0	0	1/89	0	0
А	3	28/76 (38.4%)	0	0	0	0	0	0
А	4	57/117 (47.9%)	2/117	0	0	0	2/117	0
А	5	9/13 (69.2%)	0	0	0	0	0	0
В	6	87/134 (64.9%)	1/134	0	0	0	0	0
В	7	12/22 (54.56%)	0	0	0	0	0	0
В	8	48/82 (58.5%)	0	0	0	1/82	0	0
В	9	0/28	1/28	0	0	0	0	0
В	10	0/40	1/40	0	0	0	0	0
С	11	9/14 (64.3%)	0	0	0	0	0	0
C	12	7/23 (30.4%)	0	0	0	1/23	0	1/23
С	13	18/25 (72%)	0	0	0	1/40	0	0

* This study includes a total cohort of 800 individuals



238

Figure 2.- Number distribution of COVID-19 cases according to age group and sex. from April 1st to July 31st (2020) at Santiago of Chile. 400 patients are considered positive for SARS-CoV-2; however, three patients did not provide any information about age and gender. In red is shows female gender and in blue is shows male gender. The numbers in the columns indicate SARS-CoV-2 positive cases by month.

245 Materials and methods

246 Sample selection

247

248 All samples in this study were obtained with nasopharyngeal swabs come from 249 suspected Chilean population infected with SARS-CoV-2 in the north of Santiago de Chile 250 from different health centers (figure 1). The samples were collected in 2 mL of RNA-251 shield media (GenoSUR) and store at room temperature until its analysis for SARS-CoV-252 2 detection. 253 RNA extraction and Identification of respiratory viruses by RT-gPCR 254 The RNA extraction was made using the Total RNA Purification Kit (Norgen Biotek CORP); 255 following the manufacturing procedure, the RNA was a store at -80°C, which was used 256 to perform RT-qPCR. 257 All samples were analyzed using a specific primer (Supplementary table 1) for SARS-CoV-258 2, IAV, IBV, RSV, and HRV. All sequences have been validated, and their use is a typical 259 procedure to detect respiratory viruses from the World Health Organization (WHO). The 260 viral genome detection was made using LightCycler® Multiplex RNA Virus Master 261 (Roche) following the manufacturing procedure. The amplification and analysis plot was 262 made in a QuantStudio3 Real Time PCR System 96 wells (Thermo Fisher Scientific). The 263 HRV and IBV detection was performed by RT-PCR final point using specific primers, the 264 retrotranscription step was made using SuperScript IV Reverse Transcriptase (Thermo 265 Fisher Scientifics) and PCR was using GoTaq[®] DNA polymerase (Promega), the genome 266 of HRV was visualized in agarose – Seakem LE Agarose (LONZA) at 2% applying a voltage

of 80 Volts for 30 minutes.

Supplementary Table 1.- Primers Sequence for SARS-CoV-2, IAV, IBV, RSV and HRV

Virus	Forward	Reverse
SARS-CoV-2	5' ATGAGCTTAGTCCTGTTG 3'	5' CTCCCTTTGTTGTGTTGT 3'
IAV,	5' GACCRATCCTGTCACCTCTGA C 3'	5' AGGGCATTYTGGACAAAKCGTCTA 3'
IBV,	5' GGAGCAACCAATGCCAC 3'	5' GTKTAGGCGGTCTTGACCAG-3'
RSV	5' AACAGATGTAAGCAGCTCCGTTATC 3'	5'- CGATTTTTATTGGATGCTGTACATTT 3'
aHRV	5'CAAGCACTTCTGTTTCCC 3'	5'CACGGACACCCAAAGTAGT 3'